Anti-HER2 antibody toxin conjugate - TopoTarget
Alternative Names: ZemabLatest Information Update: 16 Jul 2010
At a glance
- Originator Novartis
- Developer TopoTarget
- Class Antineoplastics; Drug conjugates; Immunotoxins
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2010 No development reported - Phase-I for Cancer in Denmark (Intratumoural)
- 15 May 2007 Phase-I clinical trials in Cancer in Denmark (Intratumoural)